Today Novo Nordisk Pharmatech announces the full year results for 2025
2025 was another important year for Novo Nordisk Pharmatech.
We achieved solid revenue growth while continuing to invest in the long-term development of our company. With a net sale of 1,04 DKK billion we achieved a revenue growth of 9% compared to 2024. It was also a year where we navigated significant and difficult change. In October we said goodbye to valued colleagues; the compassion, professionalism and mutual support shown during this period are a strong testament to our culture.
You can read the full annual report here.
